Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025

SOTA-P-CARDIA shows sotagliflozin improves LV mass, exercise capacity, and quality of life in non-diabetic HFpEF, supporting dual SGLT1/2 inhibition.

placeholder
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free